[go: up one dir, main page]

ES2188214T3 - Composicion antioxidante que comprende acetil l-carnitina y acido alfa-lipoico. - Google Patents

Composicion antioxidante que comprende acetil l-carnitina y acido alfa-lipoico.

Info

Publication number
ES2188214T3
ES2188214T3 ES99939612T ES99939612T ES2188214T3 ES 2188214 T3 ES2188214 T3 ES 2188214T3 ES 99939612 T ES99939612 T ES 99939612T ES 99939612 T ES99939612 T ES 99939612T ES 2188214 T3 ES2188214 T3 ES 2188214T3
Authority
ES
Spain
Prior art keywords
carnitine
lipoic acid
alpha
oil
composition including
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99939612T
Other languages
English (en)
Other versions
ES2188214T5 (es
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau HealthScience SpA
Original Assignee
Sigma Tau HealthScience SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11406116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2188214(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau HealthScience SpA filed Critical Sigma Tau HealthScience SpA
Application granted granted Critical
Publication of ES2188214T3 publication Critical patent/ES2188214T3/es
Publication of ES2188214T5 publication Critical patent/ES2188214T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición en combinación la cual comprende: (a) acetil L-carnitina o una sal farmacológicamente aceptable de la misma; y (b) ácido a-lipoico en una relación en peso sinérgicamente eficaz.
ES99939612T 1998-09-01 1999-08-19 Composicion antioxidante que comprende acetil l-carnitina y acido alfa-lipoico. Expired - Lifetime ES2188214T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998RM000566A IT1302307B1 (it) 1998-09-01 1998-09-01 Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
ITRM98A0566 1998-09-01

Publications (2)

Publication Number Publication Date
ES2188214T3 true ES2188214T3 (es) 2003-06-16
ES2188214T5 ES2188214T5 (es) 2010-06-08

Family

ID=11406116

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99939612T Expired - Lifetime ES2188214T5 (es) 1998-09-01 1999-08-19 Composicion antioxidante que comprende acetil l-carnitina y acido alfa-lipoico.

Country Status (28)

Country Link
US (1) US6365622B1 (es)
EP (1) EP1112005B2 (es)
JP (1) JP4361215B2 (es)
KR (1) KR20010079699A (es)
CN (1) CN1315835A (es)
AR (1) AR022076A1 (es)
AT (1) ATE228312T1 (es)
AU (1) AU773424B2 (es)
BR (1) BR9913288A (es)
CA (1) CA2341973C (es)
CZ (1) CZ2001541A3 (es)
DE (1) DE69904208T3 (es)
DK (1) DK1112005T4 (es)
EE (1) EE200100113A (es)
ES (1) ES2188214T5 (es)
HK (1) HK1039730A1 (es)
HU (1) HU229165B1 (es)
IL (1) IL141435A0 (es)
IS (1) IS5850A (es)
IT (1) IT1302307B1 (es)
MA (1) MA25284A1 (es)
NO (1) NO20010954L (es)
PL (1) PL212737B1 (es)
PT (1) PT1112005E (es)
SK (1) SK2632001A3 (es)
TN (1) TNSN99163A1 (es)
TR (1) TR200100610T2 (es)
WO (1) WO2000011968A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
WO2001021208A1 (en) 1999-09-23 2001-03-29 Juvenon Corporation Nutritional supplement for increased energy and stamina
EP1248609A4 (en) * 1999-11-03 2007-08-01 Juvenon Inc METHOD FOR TREATING THE GOOD MEMORY TROUBLESHOOTING
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
DE10036797A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Verwendung von Kombinationen mit einem Gehalt an Carnitinen
CA2427470A1 (en) * 2000-10-31 2002-06-06 Colgate-Palmolive Company Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin c or vitamin e for preventing or inhibiting loss of cognitive function
US20020076470A1 (en) 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
JP2010142237A (ja) * 2000-10-31 2010-07-01 Colgate Palmolive Co 組成物及び方法
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
MXPA03007802A (es) * 2001-03-09 2003-12-08 Nestle Sa Composicion que mejora las deficiencias fisiologicas relacionadas con la edad y que incrementa la longevidad.
SE0102380D0 (sv) * 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
US6923960B2 (en) * 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
IL162505A0 (en) * 2001-12-19 2005-11-20 The Quigley Corp Method for treatment of peripheral neural and vascular ailments
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
WO2003072052A2 (en) * 2002-02-22 2003-09-04 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
EP1558199A4 (en) * 2002-10-11 2006-06-28 Creagri Inc THERAPEUTIC COMBINATION OF CARNITINE AND POLYPHENOL ANTIOXIDANTS
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
DE10258239A1 (de) * 2002-12-13 2004-06-24 Degussa Ag Formulierung enthaltend alpha-Liponsäure(-Derivate) als alleinigen Wirkstoff bei nichtchronischen alkoholinduzierten Intoxikationen
US20040265345A1 (en) * 2003-06-30 2004-12-30 Perricone Nicholas V. Treatment of skin damage using acetyl carnitine and lipoic acid
US20050214413A1 (en) * 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
US7999003B2 (en) * 2003-08-26 2011-08-16 Mannatech, Incorporated Antioxidant compositions and methods thereto
US20050142124A1 (en) * 2003-12-31 2005-06-30 Kaiser Jon D. Nutrient compositions and methods for enhanced effectiveness of the immune system
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
RU2394561C2 (ru) * 2004-11-24 2010-07-20 Хилл`С Пет Ньютришн, Инк. Способы увеличения иммунного ответа у животного
AU2005309435B2 (en) * 2004-11-24 2011-09-22 Hill's Pet Nutrition, Inc. Methods for improving liver clearance of xenobiotic substances in an animal
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
ES2436181T3 (es) 2004-12-29 2013-12-27 Hill's Pet Nutrition Inc. Métodos para inhibir un declive en el aprendizaje y/o la memoria en animales
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
JP5295567B2 (ja) * 2004-12-30 2013-09-18 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 高齢期の動物の生活の質を高めるための方法
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
DK1906912T3 (da) 2005-07-14 2012-12-03 Hills Pet Nutrition Inc Fremgangsmåde til forlængelse af et dyrs levetid
CA2664982C (en) * 2006-02-23 2015-12-29 Nou-Life Sciences, Inc. Cleavable carnitine compound
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
CN101057857B (zh) * 2006-04-21 2011-05-18 中国科学院上海生命科学研究院 一种预防与改善帕金森氏症的组合物及其制法
KR100811110B1 (ko) * 2007-02-21 2008-03-06 주식회사 디피아이 솔루션스 수분산성 α-리포산 캡슐 조성물을 함유하는 어류의 면역력증강용 사료첨가제 및 그 사용방법.
US20080226696A1 (en) * 2007-03-15 2008-09-18 Ben Treadwell Methods of improving learning abilities of aged companion animals
KR20090014568A (ko) * 2007-08-06 2009-02-11 (주)바이오제닉스 코팅된 알파리포산 입자, 이를 포함하는 조성물 및 그 제조방법
US20100255109A1 (en) * 2007-08-06 2010-10-07 Biogenics, Inc. Stabilized antioxidant particles, composition comprising the same and method for preparing the same
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
KR100903549B1 (ko) * 2008-07-29 2009-06-23 주식회사 카이로제닉스 균질한 결정성의 아세틸-ｌ-카르니틴과 티옥트산 칼륨염의 복합염, 이의 제조방법 및 이를 포함하는 약학적 조성물
US20110217252A1 (en) * 2008-11-11 2011-09-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
EP2389931A1 (en) * 2010-05-21 2011-11-30 Raw Materials Internatinal LLC Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
PT2787969T (pt) 2011-12-07 2021-11-09 Allergan Inc Entrega eficiente de lípidos para o filme lacrimal humano utilizando um sistema de emulsão sensível ao sal
US20140371280A1 (en) * 2013-03-15 2014-12-18 Shinichi Okuyama Method of treating diabetic peripheral neuropathy through amendment of pre-neuronal diabetic coagulative micro-angiopathy and neuronal deficiency of mitochondrial ATP production, and through induction of neuronal regeneration
US20190290609A1 (en) * 2014-03-19 2019-09-26 Epitech Group S.P.A. Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
CA2965671A1 (en) 2014-10-24 2016-04-28 Robert Shorr Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
CA2967413C (en) 2014-11-25 2023-08-15 Allergan, Inc. Ophthalmic compositions containing omega-3 oils stabilized by antioxidants
US10413526B2 (en) 2015-03-31 2019-09-17 Kolinpharma S.P.A. Composition for the treatment of neuropathies and/or neuropathic pain
KR102862875B1 (ko) * 2015-08-24 2025-09-19 비트로라이프 스웨덴 에이비 배양 배지
US11998554B2 (en) * 2018-09-10 2024-06-04 URIACH ITALY S.r.l. Composition comprising lipoic acid and vitamin D for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies
CN111467385B (zh) * 2019-01-24 2022-05-17 深圳市华大农业应用研究院 组合物在预防或治疗神经退行性疾病中的用途
US20220193098A1 (en) * 2019-04-18 2022-06-23 Simo Rasi Composition for use in prevention or reduction of oxidative stress and neurodegenerative diseases
WO2022215085A1 (en) * 2021-04-06 2022-10-13 Celagenex Research (India) Pvt. Ltd. A synergistic composition for potentiating stabilized atp
CN112999220B (zh) * 2021-04-07 2022-12-13 中国人民解放军南部战区总医院 α-硫辛酸在作为和/或制备金属β-内酰胺酶抑制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
AU6482596A (en) 1995-07-03 1997-02-05 Wilson T. Crandall Transdermal and oral treatment of androgenic alopecia
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US5977162A (en) 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress

Also Published As

Publication number Publication date
CZ2001541A3 (cs) 2001-09-12
HU229165B1 (en) 2013-09-30
US6365622B1 (en) 2002-04-02
HUP0102909A2 (hu) 2002-03-28
AU773424B2 (en) 2004-05-27
NO20010954L (no) 2001-04-25
SK2632001A3 (en) 2001-08-06
ATE228312T1 (de) 2002-12-15
EP1112005A1 (en) 2001-07-04
CA2341973A1 (en) 2000-03-09
EP1112005B1 (en) 2002-11-27
ES2188214T5 (es) 2010-06-08
WO2000011968A8 (en) 2000-05-11
IL141435A0 (en) 2002-03-10
ITRM980566A1 (it) 2000-03-01
AU5387199A (en) 2000-03-21
NO20010954D0 (no) 2001-02-26
PT1112005E (pt) 2003-03-31
ITRM980566A0 (it) 1998-09-01
DK1112005T3 (da) 2002-12-30
HUP0102909A3 (en) 2002-12-28
TR200100610T2 (tr) 2001-07-23
PL346318A1 (en) 2002-01-28
KR20010079699A (ko) 2001-08-22
DK1112005T4 (da) 2010-06-14
CN1315835A (zh) 2001-10-03
CA2341973C (en) 2009-05-12
DE69904208T3 (de) 2010-09-30
IT1302307B1 (it) 2000-09-05
EE200100113A (et) 2002-06-17
HK1039730A1 (zh) 2002-05-10
BR9913288A (pt) 2001-05-22
TNSN99163A1 (fr) 2005-11-10
JP2002523435A (ja) 2002-07-30
EP1112005B2 (en) 2010-03-24
AR022076A1 (es) 2002-09-04
IS5850A (is) 2001-02-16
JP4361215B2 (ja) 2009-11-11
WO2000011968A1 (en) 2000-03-09
DE69904208D1 (de) 2003-01-09
DE69904208T2 (de) 2003-08-28
PL212737B1 (pl) 2012-11-30
MA25284A1 (fr) 2001-12-31

Similar Documents

Publication Publication Date Title
ES2188214T3 (es) Composicion antioxidante que comprende acetil l-carnitina y acido alfa-lipoico.
BR9807742A (pt) EpotilÈneos que são modificados na cadeia lateral
ES2182126T3 (es) ..mposiciones dentifricas que contienen polifosfato y fluoruro
BR9810658A (pt) Composições farmacêuticas contendo hemissulfato de eletriptano e cafeìna.
BR9713212A (pt) Suplementos alimentares contendo flavonol
ECSP045154A (es) Composiciones de fórmula para infantes que comrende cantidades aumentadas de alfa - lactalbumin
ES2162614T1 (es) Composiciones formadoras de pelicula que comprenden almidones modificados e iota-carragaenina y metodo para producir capsulas blandas usando las mismas.
AR002350A1 (es) Composiciones farmacéuticas que contienen irbesartan
DZ2614A1 (fr) Compositions pharmaceutiques topiques contenant des dérivés de résorcinol.
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
FI970825L (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
KR870006891A (ko) 구강 위생 조성물
ES2188177T3 (es) Composicion para la prevencion y/o el tratamiento de la osteoporosis y las alteraciones debidas al sindrome menopausico, que comprende propionil-l-carnitina y genisteina.
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
EP1072608A4 (en) GLUTATHIONE DERIVATIVES AND THEIR DOSAGE FORM
ES2187070T3 (es) Composiciones de laca para el cabello autofobas.
ES2169505T3 (es) Pasta de dientes con alto contenido de humedad.
YU11401A (sh) Lokalne farmaceutske kompozicije koje sadrže nimesulid
DK0842165T3 (da) Thiazolidin-4-carboxylsyrederivater som cytobeskyttende midler
AU4271999A (en) Package surprise designed to contain objects
ES2194933T3 (es) Inhibidores de la agregacion plaquetaria.
AR013411A1 (es) Composicion de aplicacion para tratamientos antivirales y afecciones micosicas y/o bacterianas y utilizacion de dichas composiciones.
BR0011261A (pt) Composição oral compreendendo perlita, e, uso de perlita
BR0112537A (pt) Preparações cosméticas de embelezamento contendo dialquilcarbonatos e óxidos de metal
MX170421B (es) Mejoras a composicion oral antibacterial